Los Angeles Capital Management LLC Has $2.55 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

Los Angeles Capital Management LLC trimmed its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 158,658 shares of the biotechnology company’s stock after selling 18,399 shares during the period. Los Angeles Capital Management LLC owned about 0.25% of Innoviva worth $2,545,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC boosted its stake in shares of Innoviva by 159.5% during the 3rd quarter. SG Americas Securities LLC now owns 32,940 shares of the biotechnology company’s stock worth $428,000 after acquiring an additional 20,248 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Innoviva by 43.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,254 shares of the biotechnology company’s stock worth $224,000 after buying an additional 5,199 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Innoviva by 3.8% in the third quarter. Assetmark Inc. now owns 54,755 shares of the biotechnology company’s stock worth $711,000 after buying an additional 2,009 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Innoviva by 71.4% during the 3rd quarter. Jennison Associates LLC now owns 85,071 shares of the biotechnology company’s stock worth $1,105,000 after buying an additional 35,430 shares during the period. Finally, Panagora Asset Management Inc. acquired a new position in Innoviva in the 3rd quarter valued at $181,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Analyst Upgrades and Downgrades

INVA has been the subject of a number of research analyst reports. TheStreet raised shares of Innoviva from a “c” rating to a “b-” rating in a research report on Thursday, February 29th. StockNews.com upgraded Innoviva from a “hold” rating to a “buy” rating in a research note on Friday, March 29th.

Innoviva Trading Up 1.6 %

Shares of Innoviva stock opened at $15.45 on Tuesday. Innoviva, Inc. has a 1 year low of $11.55 and a 1 year high of $16.86. The company’s fifty day simple moving average is $14.97 and its 200-day simple moving average is $15.04. The company has a market cap of $976.90 million, a price-to-earnings ratio of 7.09 and a beta of 0.57. The company has a current ratio of 9.03, a quick ratio of 7.96 and a debt-to-equity ratio of 0.66.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Thursday, February 29th. The biotechnology company reported $0.76 earnings per share for the quarter. Innoviva had a net margin of 57.89% and a return on equity of 30.37%. The firm had revenue of $85.84 million during the quarter.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.